title: Effects of L-DOPA on nigral dopamine neurons and local field potential: comparison with apomorphine and muscimol.
abstract: L-DOPA is more effective than direct dopamine (DA) agonists in relieving the motor deficits in Parkinson's disease. Using in vivo recording, we compared the effect of l-DOPA and the direct DA agonist apomorphine on DA neurons in rat substantia nigra (SN). L-DOPA (50-100 mg/kg i.v.) decreased the firing rate as well as the variability and slow oscillation (SO) of firing. All effects were blocked by raclopride and mimicked by quinpirole, suggesting that they are mediated through D2-like receptors. Autoreceptor-selective doses of apomorphine (5-20 μg/kg i.v.) also inhibited all three parameters. The magnitude of the inhibition, however, was significantly greater than that induced by L-DOPA. Neither L-DOPA nor apomorphine had a consistent effect on SN local field potentials (LFPs). The GABA agonist muscimol, known to preferentially inhibit SN non-DA neurons, consistently inhibited the SO in both DA cell firing and LFPs. These results suggest that SN LFPs mainly reflect the synaptic potentials in non-DA neurons, and L-DOPA and apomorphine, unlike muscimol, affect DA neurons primarily through DA autoreceptors. DA autoreceptor activation is known to hyperpolarize DA cells by increasing the membrane conductance to K(+). This increase in membrane conductance would shunt synaptic input to DA neurons, thereby decreasing the variability and SO in DA cell firing. The low potency of L-DOPA to inhibit DA cell firing and reduce their responses to synaptic input may partially account for its superior therapeutic efficacy in Parkinson's disease compared with apomorphine and other direct DA agonists.
authors.affiliation: Department of Pharmaceutical Sciences, Loma Linda University School of Pharmacy, 11175 Campus St., Loma Linda, CA 92350, USA.
authors.forename: Dan
authors.initials: D
authors.lastname: Xu
authors.forename: Bradley
authors.initials: B
authors.lastname: Karain
authors.forename: Eileen
authors.initials: E
authors.lastname: Brantley
authors.forename: Wei-Xing
authors.initials: WX
authors.lastname: Shi
mesh_terms: D000818:Animals; D001058:Apomorphine / Q000494:pharmacology*; D004298:Dopamine / Q000502:physiology*; D015259:Dopamine Agents / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D055724:Electrophysiological Phenomena; D005071:Evoked Potentials / Q000187:drug effects; D018755:GABA Agonists / Q000494:pharmacology*; D007980:Levodopa / Q000494:pharmacology*; D008297:Male; D009118:Muscimol / Q000494:pharmacology*; D009474:Neurons / Q000187:drug effects*; D010302:Parkinson Disease, Secondary / Q000188:drug therapy / Q000503:physiopathology; D020891:Raclopride / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011954:Receptors, Dopamine / Q000187:drug effects; D013378:Substantia Nigra / Q000166:cytology* / Q000187:drug effects
chemical_list: D015259:Dopamine Agents; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D018755:GABA Agonists; D011954:Receptors, Dopamine; D009118:Muscimol; D020891:Raclopride; D007980:Levodopa; D001058:Apomorphine; D004298:Dopamine